China grants BTD to Blenrep with BorDex for multiple myeloma
China's NMPA grants GSK's Blenrep breakthrough therapy designation for relapsed or refractory multiple myeloma treatment, based on Phase III DREAMM-7 trial results showing significant PFS improvements.
Reference News
China grants BTD to Blenrep with BorDex for multiple myeloma
China's NMPA grants GSK's Blenrep breakthrough therapy designation for relapsed or refractory multiple myeloma treatment, based on Phase III DREAMM-7 trial results showing significant PFS improvements.